Published in Arch Intern Med on November 12, 2001
Antiallodynic Effect of Thalidomide and Morphine on Rat Spinal Nerve Ligation-induced Neuropathic Pain. Korean J Pain (2010) 0.89
Thalidomide has activity in treating complex regional pain syndrome. Arch Intern Med (2003) 0.82
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia (2007) 3.95
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med (1997) 2.66
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia (2009) 2.28
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia (2011) 2.12
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol (2001) 2.10
Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 2.02
Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol (2001) 2.00
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia (2009) 1.97
Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer (2000) 1.95
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia (2011) 1.92
Primary renal non-Hodgkin's lymphoma. An unusual extranodal site. Cancer (1995) 1.82
True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood (1995) 1.81
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia (2007) 1.79
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia (2006) 1.71
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Clinical significance of TP53 mutation in myeloma. Leukemia (2007) 1.62
Thalidomide in the treatment of plasma cell malignancies. J Clin Oncol (2001) 1.59
Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia (2008) 1.56
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia (2013) 1.54
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia (2005) 1.51
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia (2011) 1.50
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol (2001) 1.45
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Osseous Hodgkin disease. Cancer (1999) 1.41
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia (2012) 1.41
Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol (2013) 1.41
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia (2006) 1.39
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia (2011) 1.38
Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia (2001) 1.36
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood (2000) 1.36
Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia (1996) 1.33
Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med (2001) 1.32
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia (2011) 1.31
Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc (2000) 1.30
Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res (2000) 1.28
Treatment of newly diagnosed myeloma. Leukemia (2008) 1.27
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia (2012) 1.27
A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc (2001) 1.27
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia (2007) 1.25
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia (2008) 1.24
Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood (1999) 1.24
Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol (1998) 1.23
Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am (1999) 1.23
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med (2000) 1.22
Expression of VEGF and its receptors by myeloma cells. Leukemia (2003) 1.18
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene (2009) 1.18
Cloning, sequencing, and expression in Ficoll-generated minicells of an Escherichia coli heat-stable enterotoxin gene. Plasmid (1988) 1.18
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia (2007) 1.18
The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia (2010) 1.15
Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia (2011) 1.15
Management of Portuguese patients with hyperplastic polyposis and screening of at-risk first-degree relatives: a contribution for future guidelines based on a clinical study. Am J Gastroenterol (2004) 1.15
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol (2001) 1.14
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia (2010) 1.14
The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood (2001) 1.12
Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry (1993) 1.11
The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol (2000) 1.10
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol (2003) 1.10